GYNECOLOGIC CANCERS

Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.

UCLA researchers have discovered a new drug that helps reduce ascites in patients with ovarian cancer through inhibiting certain receptors.

Patients with ovarian cancer who have high-to-medium expression of folate receptor alpha responded well overall to mirvetuximab soravtansine.

Neoadjuvant chemotherapy is increasingly used in advanced ovarian cancer, even though it has not been shown to improve survival versus primary cytoreduction.

Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.

While immune checkpoint inhibitors initially showed promise in patients with ovarian cancer, results still need to be validated by larger randomized trials.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, talks about use of PD-1 inhibitors in ovarian cancer and the lack of evidence pointing toward their functionality.

Acute lymphoblastic leukemia (ALL) is a relatively rare malignancy in adults, with an estimated 6250 new cases and 1450 deaths expected in the United States in 2015. Although most patients achieve complete remission with conventional combination chemotherapy regimens, at least two-thirds of high-risk patients relapse.2 While overall survival for children has significantly improved in the last 30 years, newly diagnosed adults continue to have a poor 5-year OS rate, approximating 35%, depending on age and risk factors.

Intensity-modulated radiation therapy (IMRT) for cervical cancer has led to a double-digit decrease in late bowel toxicity compared with 3-D conformal radiation therapy without statistical significance.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted breakthrough therapy designation by the FDA as a potential treatment for relapsed or refractory acute lymphoblastic leukemia patients.

Researchers note that chronic Hedgehog (Hh) pathway stimulation has been shown in prostate, lung, and ovarian cancers, and that zinc levels decrease early in prostate cancer continuing to castration-resistant disease. Researchers are exploring whether or not zinc may suppress the autocatalysis in the Hh precursor and inhibit production of biologically active Hh ligand.

The USPSTF recently posted a draft recommendation statement and draft evidence review on screening for colorectal cancer prompting responses from organizations and industry.

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses unanswered questions regarding the treatment of patients with uterine cancer.

A more than 25-month improvement in overall survival was seen with lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) combined with optimized (?45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Frederic Amant, MD, PhD, assistant professor, gynecologic oncologist, head of the scientific section of gynecologic oncology at Katholieke Universiteit in Leuven, Belgium, the impacts of chemotherapy on pregnant woman and their babies.

Tom Herzog, MD, clinical director, University of Cincinnati Cancer Institute, explains the impact ADXS11-001 may have on patients with recurrent metastatic cervical cancer who currently have limited effective treatment options.

Significantly improved emesis control was seen when fosaprepitant was added to an antiemetic regimen compared with standard care, in women receiving radiotherapy and cisplatin for cervical cancer.

Treatment with nivolumab demonstrated clinical efficacy and safety in patients with platinum-resistant, recurrent, or advanced ovarian cancer.

Patients with advanced lung and gastrointestinal neuroendocrine tumors had a 52% reduction in risk of progression or death with everolimus compared with placebo.

A novel immunotherapy, EGEN-001, combined with pegylated liposomal doxorubicin (PLD) has demonstrated clinical benefit in recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients.

The fully human PD-L1 IgG1 antibody, avelumab, demonstrated clinical activity in patients who have previously treated, recurrent/refractory (R/R) ovarian cancer.

Results of the CHORUS trial confirm the noninferiority of primary chemotherapy followed by surgery versus primary surgery and then chemotherapy, and show that performing chemotherapy first is associated with less morbidity and mortality in patients with newly diagnosed, advanced ovarian cancer.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

A novel basket trial has reported results on the treatment of vemurafenib in variety of nonmelanoma cancers with BRAF V600 mutation.

Patients with epithelial ovarian cancer who took non-selective beta blockers (NSBBs) during chemotherapy had significantly improved overall survival (OS) than those who did not.

Young black women have a higher prevalence of BRCA mutations compared with that previously reported among non-Hispanic white women.

Recent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Sonidegib (Odomzo) was approved by the EC for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) and are not amenable to curative surgery or radiation therapy.

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses the challenges of treating HPV-induced tumors.